                         SEQUENCE LISTING

<110>  BRISTOL-MYERS SQUIBB COMPANY
 
<120>  TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY 
       AND IL-6

<130>  12558-WO-PCT

<150>  62/190322
<151>  2015-07-09

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  2555
<212>  DNA
<213>  Homo sapiens

<400>  1
cccgctctgg ccccaccctc accctccaac aaagatttat caaatgtggg attttcccat       60

gagtctcaat attagagtct caacccccaa taaatatagg actggagatg tctgaggctc      120

attctgccct cgagcccacc gggaacgaaa gagaagctct atctcccctc caggagccca      180

gctatgaact ccttctccac aagtaagtgc aggaaatcct tagccctgga actgccagcg      240

gcggtcgagc cctgtgtgag ggaggggtgt gtggcccagg gagggctggc gggcggccag      300

cagcagaggc aggctcccag ctgtgctgtc agctcacccc tgcgctcgct cccctccggc      360

acaggcgcct tcggtccagt tgccttctcc ctggggctgc tcctggtgtt gcctgctgcc      420

ttccctgccc cagtaccccc aggagaagat tccaaagatg tagccgcccc acacagacag      480

ccactcacct cttcagaacg aattgacaaa caaattcggt acatcctcga cggcatctca      540

gccctgagaa aggagacatg taacaagagt aacatgtgtg aaagcagcaa agaggcactg      600

gcagaaaaca acctgaacct tccaaagatg gctgaaaaag atggatgctt ccaatctgga      660

ttcaatgagg agacttgcct ggtgaaaatc atcactggtc ttttggagtt tgaggtatac      720

ctagagtacc tccagaacag atttgagagt agtgaggaac aagccagagc tgtgcagatg      780

agtacaaaag tcctgatcca gttcctgcag aaaaaggtgg gtgtgtcctc attccctcaa      840

cttggtgtgg gggaagacag gctcaaagac agtgtcctgg acaactcagg gatgcaatgc      900

cacttccaaa agagaaggct acacgtaaac aaaagagtct gagaaatagt ttctgattgt      960

tattgttaaa tctttttttg tttgtttggt tggttggctc tcttctgcaa aggacatcaa     1020

taactgtatt ttaaactata tattaactga ggtggatttt aacatcaatt tttaatagtg     1080

caagagattt aaaaccaaag gcgggggggc gggcagaaaa aagtgcatcc aactccagcc     1140

agtgatccac agaaacaaag accaaggagc acaaaatgat tttaagattt tagtcattgc     1200

caagtgacat tcttctcact gtggttgttt caattctttt tcctaccttt taccagagag     1260

ttagttcaga gaaatggtca gagactcaag ggtggaaaga ggtaccaaag gctttggcca     1320

ccagtagctg gctattcaga cagcagggag tagacttgct ggctagcatg tggaggagcc     1380

aaagctcaat aagaaggggc ctagaatgaa acccttggtg ctgatcctgc ctctgccatt     1440

tctacttaag ccagggtttc tcatatgtta acatgcatgg gaattccctg ggcatcttct     1500

tgtggtgtgg agtctgactt agcaagcctc gggtgggttt gagggtcaaa tttctaccag     1560

gcttatatcc ctggtgatgc tgcagaattc caggaccaca cttggaggtt taaggccttc     1620

cacaagttac ttatcccata tggtgggtct atggaaaggt gtttcccagt cctctttaca     1680

ccaccggatc agtggtcttt caacagatcc taaagggatg gtgagaggga aactggagaa     1740

aagtatcaga tttagaggcc actgaagaac ccatattaaa atgcctttaa gtatgggctc     1800

ttcattcata tactaaatat gaactatgtg ccaggcatta tttcatatga cagaatacaa     1860

acaaataaga tagtgatgct ggtcaggctt ggtggctcat gcctgtattc cctaaacttt     1920

gggagcctaa ggtgagaact ccttgaactc ctaaggccag gagttcaaga ccagcctgga     1980

taacatagca agaccccatc tctacaaaaa accaaaacca aacaaacaaa aatgatagtg     2040

gtgcttccct caggatgctt gtggtctaat gggagacaga acagcaaagg gatgattaga     2100

agttggttgc tgtgagccag gcacagtgct gatataatcc cagcgctatg ggaggctgag     2160

gtgggtggat catttgaggc caggagttta agaccagcct ggtcaacatg gtaaaacccc     2220

atctctactt aaaaatacaa aaaagttagc caggcatggt ggcatacacc tgtaacccag     2280

ctactcagga ggctgaggca catgaatcac ttgaacccag gaggcagagg ttgctgtgca     2340

ccactgcact ccagcctggg tgacagaacg agaccttgac tcaaaaaaaa aaaaaagaag     2400

tttgttgcta tggaagggtc ctactcagag caggcacccc agttaatctc attcacccca     2460

catttcacat ttgaacatca tcccatagcc cagagcatcc ctccactgca aaggatttat     2520

tcaacattta aacaatcctt tttactttca ttttc                                2555


<210>  2
<211>  252
<212>  PRT
<213>  Homo sapiens

<400>  2

Met Asn Ser Phe Ser Thr Ser Lys Cys Arg Lys Ser Leu Ala Leu Glu 
1               5                   10                  15      


Leu Pro Ala Ala Val Glu Pro Cys Val Arg Glu Gly Cys Val Ala Gln 
            20                  25                  30          


Gly Gly Leu Ala Gly Gly Gln Gln Gln Arg Gln Ala Pro Ser Cys Ala 
        35                  40                  45              


Val Ser Ser Pro Leu Arg Ser Leu Pro Ser Gly Thr Gly Ala Phe Gly 
    50                  55                  60                  


Pro Val Ala Phe Ser Leu Gly Leu Leu Leu Val Leu Pro Ala Ala Phe 
65                  70                  75                  80  


Pro Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro 
                85                  90                  95      


His Arg Gln Pro Leu Thr Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg 
            100                 105                 110         


Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys 
        115                 120                 125             


Ser Asn Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu 
    130                 135                 140                 


Asn Leu Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe 
145                 150                 155                 160 


Asn Glu Glu Thr Cys Leu Val Lys Ile Ile Thr Gly Leu Leu Glu Phe 
                165                 170                 175     


Glu Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu 
            180                 185                 190         


Gln Ala Arg Ala Val Gln Met Ser Thr Lys Val Leu Ile Gln Phe Leu 
        195                 200                 205             


Gln Lys Lys Val Gly Val Ser Ser Phe Pro Gln Leu Gly Val Gly Glu 
    210                 215                 220                 


Asp Arg Leu Lys Asp Ser Val Leu Asp Asn Ser Gly Met Gln Cys His 
225                 230                 235                 240 


Phe Gln Lys Arg Arg Leu His Val Asn Lys Arg Val 
                245                 250         


